Vikram Purohit
Stock Analyst at Morgan Stanley
(1.95)
# 3,332
Out of 5,182 analysts
163
Total ratings
36.36%
Success rate
-5.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Maintains: Overweight | $18 → $16 | $8.85 | +80.79% | 4 | Mar 25, 2026 | |
| INCY Incyte | Maintains: Equal-Weight | $92 → $94 | $94.24 | -0.25% | 26 | Jan 6, 2026 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $31 → $34 | $18.11 | +87.74% | 3 | Oct 28, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $80 → $79 | $63.76 | +23.90% | 11 | Oct 20, 2025 | |
| ABSI Absci | Maintains: Overweight | $6.4 → $5.89 | $4.81 | +22.45% | 3 | Aug 18, 2025 | |
| RXRX Recursion Pharmaceuticals | Assumes: Equal-Weight | $5 | $3.47 | +44.09% | 4 | Jul 3, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $223.84 | +11.69% | 19 | May 5, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $185.20 | +2.59% | 19 | Feb 27, 2025 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $5.24 | +71.92% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $26.46 | +17.16% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $16 | $112.00 | -85.71% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $23.64 | -57.70% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $8.73 | +381.10% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $85.78 | -52.20% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $8.23 | +386.03% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $1.87 | +597.05% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $12.25 | +210.20% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $6.13 | +226.26% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $16.77 | -40.37% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.27 | +1,632.28% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $20.74 | -3.57% | 2 | Aug 5, 2020 |
COMPASS Pathways
Mar 25, 2026
Maintains: Overweight
Price Target: $18 → $16
Current: $8.85
Upside: +80.79%
Incyte
Jan 6, 2026
Maintains: Equal-Weight
Price Target: $92 → $94
Current: $94.24
Upside: -0.25%
Zenas BioPharma
Oct 28, 2025
Maintains: Overweight
Price Target: $31 → $34
Current: $18.11
Upside: +87.74%
Halozyme Therapeutics
Oct 20, 2025
Maintains: Overweight
Price Target: $80 → $79
Current: $63.76
Upside: +23.90%
Absci
Aug 18, 2025
Maintains: Overweight
Price Target: $6.4 → $5.89
Current: $4.81
Upside: +22.45%
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $3.47
Upside: +44.09%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $223.84
Upside: +11.69%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $185.20
Upside: +2.59%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $5.24
Upside: +71.92%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $26.46
Upside: +17.16%
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $112.00
Upside: -85.71%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $23.64
Upside: -57.70%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $8.73
Upside: +381.10%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $85.78
Upside: -52.20%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $8.23
Upside: +386.03%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $1.87
Upside: +597.05%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $12.25
Upside: +210.20%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $6.13
Upside: +226.26%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $16.77
Upside: -40.37%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.27
Upside: +1,632.28%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $20.74
Upside: -3.57%